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Identity 
Other names: SHFM1D 
HGNC (Hugo): DLX5 
Location: 7q21.3 
Local order: -DLX6-DLX5-ACN9- 
DNA/RNA 
Description 
The DLX5 gene is composed of 3 exons spanning a 
genomic region of 4442 bp. 
Transcription 
The DLX5 coding sequence consists of 870 bp from 
the start of the first codon to the stop codon (Simeone 





The DLX5 protein consists of 289 amino acids with a 
calculated molecular weight of 31,5 kDa.  
The protein contains two motifs, one dubbed homeobox 
protein distal-less-like N terminal and a second known 




Transcription factor important in the control of bone 
formation in embryonic development (Hassan et al., 
2004). 
Homology 
None reported to date. 
 
 
Local order of DLX5 and flanking genes DLX6 and ACN9 is shown, with centromere at left and telomere (qter) at right. Arrows indicate 
transcriptional orientation of individual genes. DLX6 gene range: 96635290 - 96640352; DLX5 gene range: 96649702 - 96654143; ACN9 
gene range: 96745905 - 96811075 (Hillier et al., 2003). 
 
Exon 1: 1 - 563; exon 2: 2463 - 2647; exon 3: 3767 - 4442. 
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A novel DLX5 mutation (c.A533C: p.Q178P) was 
identified in a family with autosomal recessive split 
hand and foot malformation (Shamseldin et al., 2012). 
Somatic 
A DLX5 mutation (c.C119G: p.S40C) was observed in 
an ovarian carcinoma (Cancer Genome Atlas Research 
Network, 2011). 
Overexpression of DLX5 has been reported in several 
types of human malignancy including lung cancer 
(Kato et al., 2008; Xu and Testa, 2009), T-cell 
lymphoma (Tan et al., 2008), and ovarian cancer (Tan 




The DLX5 gene was reported to be overexpressed in 
the great majority of human non-small cell lung cancers 
examined by Kato et al., 2008. Furthermore, 
immunohistochemical studies revealed that positive 
immunostaining for DLX5 correlated with tumor size 
and poorer prognosis. 
Lymphoma 
Note 
DLX5 was found to be highly expressed in 3 of 7 
(42%) patient-derived T-cell lymphomas compared 
with that observed in nonmalignant lymph node 
samples (Tan et al., 2008). In addition, these 
investigators found repeated upregulation of Dlx5 in T-
cell lymphomas from transgenic mice in which the Lck 
promoter was used to drive expression of a 
constitutively active form of Akt2 in the thymus. Dlx5 
was overexpressed due to a novel chromosome 
inversion that placed the T-cell receptor beta (Tcrb) 
enhancer region near the Dlx5 locus. 
Breast cancer 
Note 
Both DLX5 and DLX6 were found to be upregulated 
during metastasis formation after intravenous injection 
of MDA-MB-231 breast cancer cells. The in vitro 
treatment of MDA-MB-231 cells with endothelin 1, a 
peptide associated with breast cancer invasive 
phenotype, resulted in a switch from DLX2 to DLX5 
expression. Mutually exclusive expression of DLX2 
and DLX5 was found in both MDA-MB-231 cells and 
human breast cancer specimens. This evidence 
suggested that DLX genes are involved in human breast 
cancer progression, and that expression of DLX2 and 
DLX5 genes might serve as prognostic markers 
(Morini et al., 2010). 
Various cancers 
Note 
DLX5 mRNA is abundantly expressed in many cancer 
cell lines derived from malignant tissues of breast, 
brain, lung, skin, and ovarian cancer patients, whereas 
expression of DLX5 was low or undetectable in tumor 
cells from patients with leukemia or with colorectal, 
prostate, and kidney cancers (Tan et al., 2010). 
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